X4 Pharmaceuticals, Inc. (XFOR) Dividend History

X4 Pharmaceuticals, Inc. (XFOR) is a biopharmaceutical company focused on developing therapies for rare diseases, particularly immune-mediated and hematologic disorders. The company's approach involves targeting mechanisms of immune regulation to address unmet medical needs in underserved patient populations.

61 North Beacon Street, Boston, MA, 02134
Phone: 857-529-8300
Website: https://www.x4pharma.com

Dividend History

X4 Pharmaceuticals, Inc. currently does not pay dividends

Company News

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals announced positive results from a six-month Phase 2 trial of its drug mavorixafor in treating chronic neutropenia. The drug durably increased participants' mean absolute neutrophil counts and enabled substantial reductions in G-CSF dosing while maintaining normal ANC levels.

GlobeNewswire Inc.
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date

GlobeNewswire Inc.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 166,353 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

GlobeNewswire Inc.
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropenia Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropenia

GlobeNewswire Inc.
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor)

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 23:50:38 UTC